Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Quality, Reproducibility, and Integrity in Early Research

Posted on November 30th, 2016 by in Pharma R&D

It is sad to hear about more paper retractions regarding early stage research with the R&D industry (1). Perhaps not surprisingly, the number of scientific publications being retracted for fraud and error has increased in recent years, at a faster rate than the rate of increased publications (2). Continue reading “Quality, Reproducibility, and Integrity in Early Research” »

The Costs of Irreproducible Biomedical Research

Posted on November 28th, 2016 by in Pharma R&D

money-case-163495_640

Issues with reproducibility plague basic biomedical research. In a June 2015 study published in PLoS Biology, the authors suggested that U.S. researchers spend $28 billion a year on research that is irreproducible. Continue reading “The Costs of Irreproducible Biomedical Research” »

How Pharma Will Be Impacted by Trump’s Healthcare Reform Plans

Posted on November 25th, 2016 by in Pharma R&D

It has only been a couple of days since Donald Trump was elected President of the United States, but the pharmaceutical and biotech industries are already wondering what might be in store for them in 2017. Continue reading “How Pharma Will Be Impacted by Trump’s Healthcare Reform Plans” »

Revolutionizing Patient Care with mHealth

Posted on November 23rd, 2016 by in Pharma R&D

Mobile technology has become an integral part of our lives, indispensable for everything from shopping to working. And now it’s quickly becoming a big part of how we manage our health. Continue reading “Revolutionizing Patient Care with mHealth” »

  1. 1
  2. 2
  3. 3
  4. 4